• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Derm Disaster

anonymous

Guest
It’s about time all the legacy losers from the Sotyktu launch started leaving and / or getting fired. Everyone knows the overlays are the real bread and butter of Sotyktu, and now that most of us will be getting our own territories, we will teach the old wood from the failed launch a lesson or 2. Just gotta be scrappy to sell this gem. Look out Otezla here we come!!!!
 




It’s about time all the legacy losers from the Sotyktu launch started leaving and / or getting fired. Everyone knows the overlays are the real bread and butter of Sotyktu, and now that most of us will be getting our own territories, we will teach the old wood from the failed launch a lesson or 2. Just gotta be scrappy to sell this gem. Look out Otezla here we come!!!!
Shut up Amgen troll